<DOC>
	<DOCNO>NCT00394056</DOCNO>
	<brief_summary>Tinnitus associate hearing loss high prevalent audiologic disorder important unmet need far therapy concern . The present study explore possible beneficial effect tinnitus loudness annoyance combination drug treatment aim increase local inhibitory activity neural circuitry involve sound perception generation . Modest effect report 8-12 week treatment antidepressant , include high dose paroxetine ( 50 mg/day ) . Biologic data suggest combination increase extracellular serotonin use SSRI blockade NK1 receptor use novel NK1 antagonist may lead reduce tinnitus , possibly , improve hearing acuity . To aim , two 14 day treatment condition , i.e. , SSRI paroxetine ( 20 mg/day ) plus NK1 antagonist vestipitant ( 25mg /day ) vestipitant alone ( 25 mg /day ) , compare placebo patient suffer tinnitus previously select capacity reliably score transient attenuation tinnitus loudness produce lidocaine infusion . Effects principal endpoint collect within 4 hr last administration , plasma level vestipitant calculate range associate pharmacodynamic effect VAS anxiety qEEG ( &gt; 30 ng/ml ) . PK , safety tolerability paroxetine-vestipitant combination address preclinical Phase I study , show relevant issue . The cross-over study require approximately 24 patient . Audiometry computer-based Automated Psychoacoustics perform instrumental endpoint support subjective score . A diary use home score tinnitus severity home study .</brief_summary>
	<brief_title>Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss .</brief_title>
	<detailed_description />
	<mesh_term>Hearing Loss</mesh_term>
	<mesh_term>Deafness</mesh_term>
	<mesh_term>Tinnitus</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Vestipitant</mesh_term>
	<criteria>Inclusion criterion : Male female subject diagnose tinnitus . Subject THI severity grade 3 4 . Subjects willing restrict alcohol intake . The subject must give write consent . Women childbearing potential abstain intercourse OR agree birth control . Women nonchildbearing potential . Exclusion criterion : Subject THI severity grade = 5 less equal 2 . Subject pathologic level anxiety depression . Subject audiogram deficit normal hearing . Subjects respond lidocaine infusion test show large variability preinfusion value . Subjects serious medical surgical condition Subjects positive drug use and/or history substance abuse dependence . Subjects take psychotropic drug antidepressant within specified time frame . Subjects recently use investigational drug recently participate trial . Subjects exhibit intolerance NK1 antagonists SSRIs . Women positive pregnancy test . Female subject intend get pregnant male subject intend father child within next 4 week follow last study drug administration study . Subjects , donate unit blood within previous month intend donate blood within one month complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>placebo</keyword>
	<keyword>balance</keyword>
	<keyword>paroxetine</keyword>
	<keyword>repeat dose</keyword>
	<keyword>Hearing Loss</keyword>
	<keyword>loudness</keyword>
	<keyword>combination</keyword>
	<keyword>Tinnitus</keyword>
	<keyword>vestipitant ( GW597599 )</keyword>
	<keyword>randomise</keyword>
	<keyword>annoyance</keyword>
	<keyword>crossover</keyword>
</DOC>